Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CDK4/6
Pharma
ASCO: Novartis details Kisqali's adjuvant breast cancer win
Adding Kisqali to endocrine therapy after surgery reduced the risk of invasive tumor recurrence or death by 25% in certain early-stage breast cancers.
Angus Liu
Jun 2, 2023 8:00am
ASCO: Merck, Novartis to face moment of truth in early cancers
May 25, 2023 3:23pm
Novartis' Kisqali, Pluvicto top list of investor concerns
Apr 25, 2023 11:22am
Eyeing Lilly, Novartis touts broader adjuvant breast cancer win
Mar 27, 2023 11:20am
FDA expands Lilly's Verzenio in early, metastatic breast cancer
Mar 6, 2023 11:01am
ASCO: Can Gilead, Pfizer and AZ-Daiichi change breast cancer?
May 31, 2022 3:30pm